Transcriptional regulation and its misregulation in Alzheimer's disease

Molecular Brain

Volumn 6, Issue 1, 2013, Pages

  Chen, Xiao Fen ^a   Zhang, Yun Wu ^a   Xu, Huaxi ^a   Bu, Guojun ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyloid ; Polymorphism; Transcription factors; Transcriptional regulatory element

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BETA SECRETASE 1; PRESENILIN 1; PRESENILIN 2;

ALZHEIMER DISEASE; BRAIN; DISEASE COURSE; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TRANSCRIPTION REGULATION; UPREGULATION;

ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEINS E; ASPARTIC ACID ENDOPEPTIDASES; GENE EXPRESSION REGULATION; HUMANS; TRANSCRIPTION, GENETIC;

EID: 84886133344     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-6-44     Document Type: Review

References (136)

1. Alzheimer's disease. Blennow K, de Leon MJ, Zetterberg H, Lancet 2006 368 387 403 10.1016/S0140-6736(06)69113-7 16876668
2. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Hardy J, Selkoe DJ, Science 2002 297 353 356 10.1126/science.1072994 12130773
3. Abeta toxicity in Alzheimer's disease. Cavallucci V, D'Amelio M, Cecconi F, Mol Neurobiol 2012 45 366 378 10.1007/s12035-012-8251-3 22415442
4. Alzheimer's disease: synapses gone cold. Koffie RM, Hyman BT, Spires-Jones TL, Mol Neurodegener 2011 6 63 10.1186/1750-1326-6-63 21871088
5. Beta-amyloid increases the expression level of ATBF1 responsible for death in cultured cortical neurons. Jung CG, Uhm KO, Miura Y, Hosono T, Horike H, Khanna KK, Kim MJ, Michikawa M, Mol Neurodegener 2011 6 47 10.1186/1750-1326-6-47 21729327
6. Biology and pathophysiology of the amyloid precursor protein. Zheng H, Koo EH, Mol Neurodegener 2011 6 27 10.1186/1750-1326-6-27 21527012
7. Gene expression endophenotypes: a novel approach for gene discovery in Alzheimer's disease. Ertekin-Taner N, Mol Neurodegener 2011 6 31 10.1186/1750-1326-6-31 21569597
8. Transcriptional regulation of Alzheimer's disease genes: implications for susceptibility. Theuns J, Van Broeckhoven C, Hum Mol Genet 2000 9 2383 2394 10.1093/hmg/9.16.2383 11005793
9. Proteolytic processing of Alzheimer's beta-amyloid precursor protein. Zhang H, Ma Q, Zhang YW, Xu H, J Neurochem 2012 120 Suppl 1 9 21 22122372
10. BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and beta-amyloid production in Alzheimer's disease. Chami L, Checler F, Mol Neurodegener 2012 7 52 10.1186/1750-1326-7-52 23039869
11. The Alzheimer's disease beta-secretase enzyme, BACE1. Cole SL, Vassar R, Mol Neurodegener 2007 2 22 10.1186/1750-1326-2-22 18005427
12. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G, Ann Neurol 2002 51 783 786 10.1002/ana.10208 12112088
13. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, et al. Nat Med 2003 9 3 4 10.1038/nm0103-3 12514700
14. Transcriptional and translational regulation of BACE1 expression-implications for Alzheimer's disease. Rossner S, Sastre M, Bourne K, Lichtenthaler SF, Prog Neurobiol 2006 79 95 111 10.1016/j.pneurobio.2006.06.001 16904810
15. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al. Science 1999 286 735 741 10.1126/science.286.5440.735 10531052
16. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, et al. Nat Neurosci 2001 4 231 232 10.1038/85059 11224535
17. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, et al. Hum Mol Genet 2001 10 1317 1324 10.1093/hmg/10.12.1317 11406613
18. BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease. Kobayashi D, Zeller M, Cole T, Buttini M, McConlogue L, Sinha S, Freedman S, Morris RG, Chen KS, Neurobiol Aging 2008 29 861 873 10.1016/j.neurobiolaging.2007.01.002 17331621
19. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, et al. J Neurosci 2005 25 11693 11709 10.1523/JNEUROSCI.2766-05.2005 16354928
20. The Alzheimer's beta-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb. Rajapaksha TW, Eimer WA, Bozza TC, Vassar R, Mol Neurodegener 2011 6 88 10.1186/1750-1326-6-88 22204380
21. Cloning and expression of the rat BACE1 promoter. Lange-Dohna C, Zeitschel U, Gaunitz F, Perez-Polo JR, Bigl V, Rossner S, J Neurosci Res 2003 73 73 80 10.1002/jnr.10639 12815710
22. Differential regulation of BACE1 expression by oxidative and nitrosative signals. Kwak YD, Wang R, Li JJ, Zhang YW, Xu H, Liao FF, Mol Neurodegener 2011 6 17 10.1186/1750-1326-6-17 21371311
23. Post-translational control of sp-family transcription factors. Waby JS, Bingle CD, Corfe BM, Curr Genomics 2008 9 301 311 10.2174/138920208785133244 19471608
24. Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S, Song W, Mol Cell Biol 2004 24 865 874 10.1128/MCB.24.2.865-874.2004 14701757
25. Measurement of the binding of transcription factor Sp1 to a single GC box recognition sequence. Letovsky J, Dynan WS, Nucleic Acids Res 1989 17 2639 2653 10.1093/nar/17.7.2639 2717405
26. Transcriptional regulation of beta-secretase-1 by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments. Chu J, Zhuo JM, Pratico D, Ann Neurol 2012 71 57 67 10.1002/ana.22625 22275252
27. A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. Perkins ND, Edwards NL, Duckett CS, Agranoff AB, Schmid RM, Nabel GJ, EMBO J 1993 12 3551 3558 8253080
28. Functional interference of Sp1 and NF-kappaB through the same DNA binding site. Hirano F, Tanaka H, Hirano Y, Hiramoto M, Handa H, Makino I, Scheidereit C, Mol Cell Biol 1998 18 1266 1274 9488441
29. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo JR, J Neurosci Res 2007 85 1194 1204 10.1002/jnr.21252 17385716
30. Nuclear factor-kappaB regulates betaAPP and beta- and gamma-secretases differently at physiological and supraphysiological Abeta concentrations. Chami L, Buggia-Prevot V, Duplan E, Delprete D, Chami M, Peyron JF, Checler F, J Biol Chem 2012 287 24573 24584 10.1074/jbc.M111.333054 22654105
31. HIF-1: an oxygen and metal responsive transcription factor. Maxwell P, Salnikow K, Cancer Biol Ther 2004 3 29 35 10.4161/cbt.3.1.547 14726713
32. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML, Science 2002 295 858 861 10.1126/science.1068592 11823643
33. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, Staufenbiel M, Huang LE, Song W, Proc Natl Acad Sci USA 2006 103 18727 18732 10.1073/pnas.0606298103 17121991
34. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. Zhang X, Zhou K, Wang R, Cui J, Lipton SA, Liao FF, Xu H, Zhang YW, J Biol Chem 2007 282 10873 10880 10.1074/jbc.M608856200 17303576
35. The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. Guglielmotto M, Aragno M, Autelli R, Giliberto L, Novo E, Colombatto S, Danni O, Parola M, Smith MA, Perry G, et al. J Neurochem 2009 108 1045 1056 10.1111/j.1471-4159.2008.05858.x 19196431
36. Salidroside attenuates hypoxia-induced abnormal processing of amyloid precursor protein by decreasing BACE1 expression in SH-SY5Y cells. Li QY, Wang HM, Wang ZQ, Ma JF, Ding JQ, Chen SD, Neurosci Lett 2010 481 154 158 10.1016/j.neulet.2010.06.076 20599477
37. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM, Proc Natl Acad Sci USA 1994 91 7355 7359 10.1073/pnas.91.15.7355 8041794
38. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Tontonoz P, Hu E, Spiegelman BM, Cell 1994 79 1147 1156 10.1016/0092-8674(94)90006-X 8001151
39. Nuclear receptors as therapeutic targets for Alzheimer's disease. Mandrekar-Colucci S, Landreth GE, Expert Opin Ther Targets 2011 15 1085 1097 10.1517/14728222.2011.594043 21718217
40. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, et al. Proc Natl Acad Sci USA 2006 103 443 448 10.1073/pnas. 0503839103 16407166
41. Inflammation, autotoxicity and Alzheimer disease. McGeer PL, McGeer EG, Neurobiol Aging 2001 22 799 809 10.1016/S0197-4580(01)00289-5 11754986
42. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Mahley RW, Science 1988 240 622 630 10.1126/science.3283935 3283935
43. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Liu CC, Kanekiyo T, Xu H, Bu G, Nat Rev Neurol 2013 9 106 118 10.1038/nrneurol. 2012.263 23296339
44. Reelin, lipoprotein receptors and synaptic plasticity. Herz J, Chen Y, Nat Rev Neurosci 2006 7 850 859 10.1038/nrn2009 17053810
45. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Chen J, Li Q, Wang J, Proc Natl Acad Sci USA 2011 108 14813 14818 10.1073/pnas.1106420108 21873229
46. Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease. Frieden C, Garai K, Proc Natl Acad Sci U S A 2012 109 8913 8918 10.1073/pnas.1207022109 22615372
47. Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. Zhong N, Weisgraber KH, J Biol Chem 2009 284 6027 6031 18948255
48. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Bu G, Nat Rev Neurosci 2009 10 333 344 10.1038/nrn2620 19339974
49. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA, Science 1993 261 921 923 10.1126/science.8346443 8346443
50. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM, JAMA 1997 278 1349 1356 10.1001/jama.1997.03550160069041 9343467
51. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. Laws SM, Hone E, Gandy S, Martins RN, J Neurochem 2003 84 1215 1236 10.1046/j.1471-4159.2003.01615.x 12614323
52. Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Taddei K, Clarnette R, Gandy SE, Martins RN, Neurosci Lett 1997 223 29 32 10.1016/S0304-3940(97)13394-8 9058415
53. Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Lindh M, Blomberg M, Jensen M, Basun H, Lannfelt L, Engvall B, Scharnagel H, Marz W, Wahlund LO, Cowburn RF, Neurosci Lett 1997 229 85 88 10.1016/S0304-3940(97)00429-1 9223597
54. Variation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E. Laws SM, Hone E, Taddei K, Harper C, Dean B, McClean C, Masters C, Lautenschlager N, Gandy SE, Martins RN, Mol Psychiatry 2002 7 886 890 10.1038/sj.mp.4001097 12232782
55. Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls. Pirttila T, Soininen H, Heinonen O, Lehtimaki T, Bogdanovic N, Paljarvi L, Kosunen O, Winblad B, Riekkinen P Sr, Wisniewski HM, Mehta PD, Brain Res 1996 722 71 77 10.1016/0006-8993(96)00183-7 8813351
56. Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. Harr SD, Uint L, Hollister R, Hyman BT, Mendez AJ, J Neurochem 1996 66 2429 2435 8632166
57. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Beffert U, Cohn JS, Petit-Turcotte C, Tremblay M, Aumont N, Ramassamy C, Davignon J, Poirier J, Brain Res 1999 843 87 94 10.1016/S0006-8993(99)01894-6 10528114
58. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Hesse C, Larsson H, Fredman P, Minthon L, Andreasen N, Davidsson P, Blennow K, Neurochem Res 2000 25 511 517 10.1023/A:1007516210548 10823584
59. Reducing human apolipoprotein E levels attenuates age-dependent Abeta accumulation in mutant human amyloid precursor protein transgenic mice. Bien-Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y, J Neurosci 2012 32 4803 4811 10.1523/JNEUROSCI.0033-12.2012 22492035
60. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM, J Neurosci 2011 31 18007 18012 10.1523/JNEUROSCI.3773-11.2011 22159114
61. Effects of an atherogenic diet on apolipoprotein E biosynthesis in the rat. Lin-Lee YC, Tanaka Y, Lin CT, Chan L, Biochemistry 1981 20 6474 6480 10.1021/bi00525a028 6171300
62. Expression of the human apolipoprotein E gene is regulated by multiple positive and negative elements. Smith JD, Melian A, Leff T, Breslow JL, J Biol Chem 1988 263 8300 8308 3372525
63. The apolipoprotein gene family: organization of upstream elements and regulation of gene expression. Surguchov AP, Biomed Sci 1990 1 344 353 2133052
64. Nucleotide sequence and structure of the human apolipoprotein E gene. Paik YK, Chang DJ, Reardon CA, Davies GE, Mahley RW, Taylor JM, Proc Natl Acad Sci USA 1985 82 3445 3449 10.1073/pnas.82.10.3445 2987927
65. Transcription factor AP-2 regulates human apolipoprotein E gene expression in astrocytoma cells. Garcia MA, Vazquez J, Gimenez C, Valdivieso F, Zafra F, J Neurosci 1996 16 7550 7556 8922411
66. ApoE promotes the proteolytic degradation of Abeta. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, et al. Neuron 2008 58 681 693 10.1016/j.neuron.2008.04.010 18549781
67. Critical role of astroglial apolipoprotein E and liver X receptor-alpha expression for microglial Abeta phagocytosis. Terwel D, Steffensen KR, Verghese PB, Kummer MP, Gustafsson JA, Holtzman DM, Heneka MT, J Neurosci 2011 31 7049 7059 10.1523/JNEUROSCI.6546-10.2011 21562267
68. Divergent effects of peroxisome proliferator-activated receptor gamma agonists and tumor necrosis factor alpha on adipocyte ApoE expression. Yue L, Rasouli N, Ranganathan G, Kern PA, Mazzone T, J Biol Chem 2004 279 47626 47632 10.1074/jbc.M408461200 15339912
69. Cell type-specific regulation of expression of transcription factor AP-2 in neuroectodermal cells. Philipp J, Mitchell PJ, Malipiero U, Fontana A, Dev Biol 1994 165 602 614 10.1006/dbio.1994.1279 7958425
70. Regulation of transcription factor AP-2 by the morphogen retinoic acid and by second messengers. Luscher B, Mitchell PJ, Williams T, Tjian R, Genes Dev 1989 3 1507 1517 10.1101/gad.3.10.1507 2482225
71. The AP-2 family of transcription factors. Eckert D, Buhl S, Weber S, Jager R, Schorle H, Genome Biol 2005 6 246 10.1186/gb-2005-6-13-246 16420676
72. Transcription factor AP-2 and monoaminergic functions in the central nervous system. Damberg M, J Neural Transm 2005 112 1281 1296 10.1007/s00702-005-0325-1 15959839
73. AP-2beta regulates amyloid beta-protein stimulation of apolipoprotein E transcription in astrocytes. Rossello XS, Igbavboa U, Weisman GA, Sun GY, Wood WG, Brain Res 2012 1444 87 95 22325097
74. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, et al. Science 2012 335 1503 1506 10.1126/science.1217697 22323736
75. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SD, Jiang XC, et al. J Neurochem 2004 88 623 634 10.1111/j.1471-4159. 2004.02183.x 14720212
76. Apolipoprotein E gene promoter polymorphisms in Alzheimer's disease. Bullido MJ, Valdivieso F, Microsc Res Tech 2000 50 261 267 10.1002/1097- 0029(20000815)50:4<261::AID-JEMT2>3.0.CO;2-B 10936877
77. Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene. Artiga MJ, Bullido MJ, Frank A, Sastre I, Recuero M, Garcia MA, Lendon CL, Han SW, Morris JC, Vazquez J, et al. Hum Mol Genet 1998 7 1887 1892 10.1093/hmg/7.12.1887 9811931
78. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Bullido MJ, Artiga MJ, Recuero M, Sastre I, Garcia MA, Aldudo J, Lendon C, Han SW, Morris JC, Frank A, et al. Nat Genet 1998 18 69 71 10.1038/ng0198-69 9425904
79. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Lambert JC, Pasquier F, Cottel D, Frigard B, Amouyel P, Chartier-Harlin MC, Hum Mol Genet 1998 7 533 540 10.1093/hmg/7.3.533 9467014
80. A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the epsilon 4 allele. Mui S, Briggs M, Chung H, Wallace RB, Gomez-Isla T, Rebeck GW, Hyman BT, Neurology 1996 47 196 201 10.1212/WNL.47.1.196 8710077
81. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. Artiga MJ, Bullido MJ, Sastre I, Recuero M, Garcia MA, Aldudo J, Vazquez J, Valdivieso F, FEBS Lett 1998 421 105 108 10.1016/S0014-5793(97)01543-3 9468288
82. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Lambert JC, Berr C, Pasquier F, Delacourte A, Frigard B, Cottel D, Perez-Tur J, Mouroux V, Mohr M, Cecyre D, et al. Hum Mol Genet 1998 7 1511 1516 10.1093/hmg/7.9.1511 9700208
83. Genomic organization of the human amyloid beta-protein precursor gene. Yoshikai S, Sasaki H, Doh-ura K, Furuya H, Sakaki Y, Gene 1990 87 257 263 10.1016/0378-1119(90)90310-N 2110105
84. Neuronal localization of amyloid beta protein precursor mRNA in normal human brain and in Alzheimer's disease. Goedert M, EMBO J 1987 6 3627 3632 3322812
85. Structural features of the 5' upstream regulatory region of the gene encoding rat amyloid precursor protein. Chernak JM, Gene 1993 133 255 260 10.1016/0378-1119(93)90648-M 8224912
86. Positive and negative regulatory elements for the expression of the Alzheimer's disease amyloid precursor-encoding gene in mouse. Izumi R, Yamada T, Yoshikai S, Sasaki H, Hattori M, Sakaki Y, Gene 1992 112 189 195 10.1016/0378-1119(92)90375-Y 1555768
87. The promoter of Alzheimer's disease amyloid A4 precursor gene. Salbaum JM, Weidemann A, Lemaire HG, Masters CL, Beyreuther K, EMBO J 1988 7 2807 2813 3053167
88. Characterization of the 5'-end region and the first two exons of the beta-protein precursor gene. La Fauci G, Lahiri DK, Salton SR, Robakis NK, Biochem Biophys Res Commun 1989 159 297 304 10.1016/0006-291X(89)92437-6 2538123
89. The initiator element and proximal upstream sequences affect transcriptional activity and start site selection in the amyloid beta-protein precursor promoter. Quitschke WW, Matthews JP, Kraus RJ, Vostrov AA, J Biol Chem 1996 271 22231 22239 10.1074/jbc.271.36.22231 8703038
90. The amyloid beta-protein precursor promoter. A region essential for transcriptional activity contains a nuclear factor binding domain. Quitschke WW, Goldgaber D, J Biol Chem 1992 267 17362 17368 1380960
91. Functional identification of the promoter of the gene encoding the Rhesus monkey beta-amyloid precursor protein. Song W, Lahiri DK, Gene 1998 217 165 176 10.1016/S0378-1119(98)00340-0 9795200
92. The expression of the amyloid precursor protein (APP) is regulated by two GC-elements in the promoter. Pollwein P, Masters CL, Beyreuther K, Nucleic Acids Res 1992 20 63 68 10.1093/nar/20.1.63 1738605
93. Two nuclear factor binding domains activate expression from the human amyloid beta-protein precursor promoter. Quitschke WW, J Biol Chem 1994 269 21229 21233 8063744
94. The zinc finger protein CTCF binds to the APBbeta domain of the amyloid beta-protein precursor promoter. Evidence for a role in transcriptional activation. Vostrov AA, Quitschke WW, J Biol Chem 1997 272 33353 33359 10.1074/jbc.272.52.33353 9407128
95. USF binds to the APB alpha sequence in the promoter of the amyloid beta-protein precursor gene. Vostrov AA, Quitschke WW, Vidal F, Schwarzman AL, Goldgaber D, Nucleic Acids Res 1995 23 2734 2741 10.1093/nar/23.14.2734 7651835
96. Overlapping binding sites of two different transcription factors in the promoter of the human gene for the Alzheimer amyloid precursor protein. Pollwein P, Biochem Biophys Res Commun 1993 190 637 647 10.1006/bbrc.1993.1096 8427604
97. Heat shock factor-1 mediates the transcriptional activation of Alzheimer's beta-amyloid precursor protein gene in response to stress. Dewji NN, Do C, Brain Res Mol Brain Res 1996 35 325 328 10.1016/0169-328X(95)00214-D 8717371
98. Interleukin-1beta and glutamate activate the NF-kappaB/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures. Grilli M, Goffi F, Memo M, Spano P, J Biol Chem 1996 271 15002 15007 10.1074/jbc.271.25.15002 8663145
99. Identification and characterization of a kappa B/Rel binding site in the regulatory region of the amyloid precursor protein gene. Grilli M, Ribola M, Alberici A, Valerio A, Memo M, Spano P, J Biol Chem 1995 270 26774 26777 10.1074/jbc.270.45.26774 7592914
100. Rac1 inhibition negatively regulates transcriptional activity of the amyloid precursor protein gene. Wang PL, Niidome T, Akaike A, Kihara T, Sugimoto H, J Neurosci Res 2009 87 2105 2114 10.1002/jnr.22039 19267423
101. Mechanism of promoter activity of the beta-amyloid precursor protein gene in different cell lines: identification of a specific 30 bp fragment in the proximal promoter region. Ge YW, Ghosh C, Song W, Maloney B, Lahiri DK, J Neurochem 2004 90 1432 1444 10.1111/j.1471-4159.2004.02608.x 15341527
102. Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. Bellingham SA, Lahiri DK, Maloney B, La Fontaine S, Multhaup G, Camakaris J, J Biol Chem 2004 279 20378 20386 10.1074/jbc.M400805200 14985339
103. Promoter polymorphisms which modulate APP expression may increase susceptibility to Alzheimer's disease. Lv H, Jia L, Jia J, Neurobiol Aging 2008 29 194 202 10.1016/j.neurobiolaging.2006.10.001 17112637
104. Secretase inhibitors and modulators for Alzheimer's disease treatment. Tomita T, Expert Rev Neurother 2009 9 661 679 10.1586/ern.09.24 19402777
105. Reconstitution of gamma-secretase activity. Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C, Nat Cell Biol 2003 5 486 488 10.1038/ncb960 12679784
106. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F, Nature 1998 391 387 390 10.1038/34910 9450754
107. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. Nature 1995 375 754 760 10.1038/375754a0 7596406
108. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, et al. Science 1995 269 973 977 10.1126/science.7638622 7638622
109. Reciprocal relationship between APP positioning relative to the membrane and PS1 conformation. Uemura K, Farner KC, Nasser-Ghodsi N, Jones P, Berezovska O, Mol Neurodegener 2011 6 15 10.1186/1750-1326-6-15 21310068
110. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Kovacs DM, Fausett HJ, Page KJ, Kim TW, Moir RD, Merriam DE, Hollister RD, Hallmark OG, Mancini R, Felsenstein KM, et al. Nat Med 1996 2 224 229 10.1038/nm0296-224 8574969
111. Expression of presenilin 1 and 2 (PS1 and PS2) in human and murine tissues. Lee MK, Slunt HH, Martin LJ, Thinakaran G, Kim G, Gandy SE, Seeger M, Koo E, Price DL, Sisodia SS, J Neurosci 1996 16 7513 7525 8922407
112. Transcriptional regulation of the mouse presenilin-1 gene. Mitsuda N, Roses AD, Vitek MP, J Biol Chem 1997 272 23489 23497 10.1074/jbc.272.38.23489 9295283
113. Structure and alternative splicing of the presenilin-2 gene. Prihar G, Fuldner RA, Perez-Tur J, Lincoln S, Duff K, Crook R, Hardy J, Philips CA, Venter C, Talbot C, et al. Neuroreport 1996 7 1680 1684 10.1097/00001756-199607080- 00031 8904781
114. An upstream element containing an ETS binding site is crucial for transcription of the human presenilin-1 gene. Pastorcic M, Das HK, J Biol Chem 1999 274 24297 24307 10.1074/jbc.274.34.24297 10446206
115. Regulation of transcription of the human presenilin-1 gene by ets transcription factors and the p53 protooncogene. Pastorcic M, Das HK, J Biol Chem 2000 275 34938 34945 10.1074/jbc.M005411200 10942770
116. Analysis of transcriptional modulation of the presenilin 1 gene promoter by ZNF237, a candidate binding partner of the Ets transcription factor ERM. Pastorcic M, Das HK, Brain Res 2007 1128 21 32 17126306
117. The C-terminal region of CHD3/ZFH interacts with the CIDD region of the Ets transcription factor ERM and represses transcription of the human presenilin 1 gene. Pastorcic M, Das HK, FEBS J 2007 274 1434 1448 10.1111/j.1742-4658. 2007.05684.x 17489097
118. Transcriptional regulation of the presenilin-1 gene: implication in Alzheimer's disease. Das HK, Front Biosci 2008 13 822 832 10.2741/2723
119. Activated cAMP-response element-binding protein regulates neuronal expression of presenilin-1. Mitsuda N, Ohkubo N, Tamatani M, Lee YD, Taniguchi M, Namikawa K, Kiyama H, Yamaguchi A, Sato N, Sakata K, et al. J Biol Chem 2001 276 9688 9698 10.1074/jbc.M006153200 11116137
120. Alzheimer-associated C allele of the promoter polymorphism -22C > T causes a critical neuron-specific decrease of presenilin 1 expression. Theuns J, Remacle J, Killick R, Corsmit E, Vennekens K, Huylebroeck D, Cruts M, Van Broeckhoven C, Hum Mol Genet 2003 12 869 877 10.1093/hmg/ddg098 12668610
121. The -48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased Abeta load in brain. Lambert JC, Mann DM, Harris JM, Chartier-Harlin MC, Cumming A, Coates J, Lemmon H, StClair D, Iwatsubo T, Lendon C, J Med Genet 2001 38 353 355 10.1136/jmg.38.6.353 11389157
122. Cloning and characterization of the presenilin-2 gene promoter. Pennypacker KR, Fuldner R, Xu R, Hernandez H, Dawbarn D, Mehta N, Perez-Tur J, Baker M, Hutton M, Brain Res Mol Brain Res 1998 56 57 65 10.1016/S0169-328X(98) 00028-X 9602061
123. Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells. Renbaum P, Beeri R, Gabai E, Amiel M, Gal M, Ehrengruber MU, Levy-Lahad E, Gene 2003 318 113 124 14585504
124. TREM2 variants in Alzheimer's disease. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. N Engl J Med 2013 368 117 127 10.1056/NEJMoa1211851 23150934
125. Variant of TREM2 associated with the risk of Alzheimer's disease. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al. N Engl J Med 2013 368 107 116 10.1056/NEJMoa1211103 23150908
126. The TREM receptor family and signal integration. Klesney-Tait J, Turnbull IR, Colonna M, Nat Immunol 2006 7 1266 1273 10.1038/ni1411 17110943
127. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. Takahashi K, Rochford CD, Neumann H, J Exp Med 2005 201 647 657 10.1084/jem.20041611 15728241
128. Cutting edge: TREM-2 attenuates macrophage activation. Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M, J Immunol 2006 177 3520 3524 16951310
129. Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. Walker DG, Link J, Lue LF, Dalsing-Hernandez JE, Boyes BE, J Leukoc Biol 2006 79 596 610 16365156
130. Transient pharmacologic lowering of Abeta production prior to deposition results in sustained reduction of amyloid plaque pathology. Das P, Verbeeck C, Minter L, Chakrabarty P, Felsenstein K, Kukar T, Maharvi G, Fauq A, Osborne BA, Golde TE, Mol Neurodegener 2012 7 39 10.1186/1750-1326-7-39 22892055
131. Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Theuns J, Brouwers N, Engelborghs S, Sleegers K, Bogaerts V, Corsmit E, De Pooter T, van Duijn CM, De Deyn PP, Van Broeckhoven C, Am J Hum Genet 2006 78 936 946 10.1086/504044 16685645
132. The many substrates of presenilin/gamma-secretase. Haapasalo A, Kovacs DM, J Alzheimers Dis 2011 25 3 28 21335653
133. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, Ciaccio PJ, Toxicol Sci 2004 82 341 358 10.1093/toxsci/kfh254 15319485
134. Inhibition of gamma-secretase worsens memory deficits in a genetically congruous mouse model of Danish dementia. Tamayev R, D'Adamio L, Mol Neurodegener 2012 7 19 10.1186/1750-1326-7-19 22537414
135. Alzheimer's disease: presenilin 2-sparing gamma-secretase inhibition is a tolerable Abeta peptide-lowering strategy. Borgegard T, Gustavsson S, Nilsson C, Parpal S, Klintenberg R, Berg AL, Rosqvist S, Serneels L, Svensson S, Olsson F, et al. J Neurosci 2012 32 17297 17305 10.1523/JNEUROSCI.1451-12.2012 23197721
136. Transcriptome profiling in neurodegenerative disease. Courtney E, Kornfeld S, Janitz K, Janitz M, J Neurosci Methods 2010 193 189 202 10.1016/j.jneumeth.2010.08.018 20800617